Vmbook Online ordering

Biotechnology

Actinium Pharmaceuticals, Inc. (ACT) is a clinical-stage biopharmaceutical company based in New York, USA. The company is focused on developing and commercializing targeted therapies for patients with unmet needs in rare and aggressive forms of cancer.

As of February 10, 2023, the company's market capitalization was approximately $53 million and its stock price was around $1.35. Over the past 52 weeks, the stock has traded between $0.68 and $3.51.

In terms of financials, ACT reported a net loss of $15.4 million for the full year 2021, compared to a net loss of $14.2 million for the full year 2020. The company's research and development expenses for 2021 were $12.3 million, an increase from $10.6 million in 2020.

In terms of growth, ACT is focused on the development of its lead product candidate, I-131-omburtamab, for the treatment of relapsed or refractory neuroblastoma, a rare form of cancer that primarily affects children. The company is currently enrolling patients in a pivotal Phase 3 clinical trial called "SIRB", and has reported positive interim data.

Additionally, ACT is also developing other product candidates, including ACT-001 for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and ACT-002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

It is important to note that investing in biotech companies, specially in clinical-stage, can be risky and volatile, it's important to conduct your own research and consider seeking the advice of a financial advisor before making any investment decisions.